Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Acasti Pharma, Inc. (NASDAQ: ACST).

Full DD Report for ACST

You must become a subscriber to view this report.


Recent News from (NASDAQ: ACST)

Acasti Pharma Schedules Second Quarter Fiscal 2019 Conference Call
LAVAL, Quebec, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST) (the “Company” or “Acasti”), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre&...
Source: GlobeNewswire
Date: November, 07 2018 08:00
Acasti Pharma Announces Closing of C$27.6 Million Underwritten Public Offering of Common Shares Including the Exercise of the Over-Allotment Option
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S. LAVAL, Quebec, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ: ACST) (TSXV: ACST) (the “ Company ” or “ Acasti ”), a biopharmaceutical innovator focused on the rese...
Source: GlobeNewswire
Date: October, 23 2018 09:00
Acasti Pharma closes $19.1M common stock offering
Acasti Pharma (NASDAQ: ACST ) closes its previous public offering of 16.6M common shares in the U.S. at a price of $1.00 per share. More news on: Acasti Pharma, Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: October, 11 2018 07:54
Acasti Pharma Announces Closing of $19.1 Million Underwritten Public Offering of Common Shares
MONTRÉAL, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe...
Source: GlobeNewswire
Date: October, 11 2018 07:30
Acasti Pharma Looks Toward Phase III for CaPre with Recent Financing, Analysts Review
NEW YORK, NY / ACCESSWIRE / October 10, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Acasti Pharma Inc. (NASDAQ: ACST), a biopharmaceutical company advancing a ...
Source: ACCESSWIRE IA
Date: October, 10 2018 08:05
Acasti Pharma prices $16.6M common stock offering
Acasti Pharma (NASDAQ: ACST ) prices its public offering of 16.6M common shares in U.S. at a price of $1.00 per share, for gross proceeds of ~$16.6M. More news on: Acasti Pharma, Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: October, 05 2018 02:08
Acasti Pharma Prices C$24 Million Underwritten Offering
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S. LAVAL, Quebec, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ: ACST) (TSXV: ACST) (the “ Company ” or “ Acasti ”) is pleased to announce that, in connection with its o...
Source: GlobeNewswire
Date: October, 04 2018 09:42
Acasti Pharma Announces Pricing of $16.6 Million Underwritten Public Offering of Common Shares
MONTREAL, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertr...
Source: GlobeNewswire
Date: October, 04 2018 09:35
Premarket Losers as of 9:05 am (10/4/2018)
OGEN -28% . More news on: Oragenics, Inc., Pain Therapeutics, vTv Therapeutics, Stocks on the move, Top stock market news, , Read more ...
Source: SeekingAlpha
Date: October, 04 2018 09:18
Acasti Pharma announces proposed underwritten public offering of common shares
Acasti Pharma ( ACST -12.9% ) intends to offer and sell its common shares in an underwritten public offering in the United States. More news on: Acasti Pharma, Inc., Neptune Technologies & Bioresources Inc, Read more ...
Source: SeekingAlpha
Date: October, 03 2018 16:34

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-170.67770.6663980.6914880.6575112,239
2018-12-140.680.670.700.6523450,532
2018-12-130.710.680.7180.68444,071
2018-12-120.66310.720.7298130.651649,275
2018-12-110.64710.650.6540.62336,992

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-176,90570,8219.7499Cover
2018-12-14142,635170,73683.5413Short
2018-12-1392,482168,00555.0472Short
2018-12-12176,384277,43463.5769Short
2018-12-1192,135170,28254.1073Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ACST.


About Acasti Pharma, Inc. (NASDAQ: ACST)

Logo for Acasti Pharma, Inc. (NASDAQ: ACST)

Not available

 

Contact Information

 

 

Current Management

  • Henri Harland / CEO, President
  • Andre Godin / CFO

Current Share Structure

  • Market Cap: $10,979,839 - 03/20/2018
  • Issue and Outstanding: 10,712,038 - 02/29/2016

 


Recent Filings from (NASDAQ: ACST)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 29 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 14 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 14 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 01 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: July, 31 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: July, 24 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: July, 02 2018
Annual and transition report of foreign private issuers under sections 13 or 15(d)
Filing Type: 20-FFiling Source: edgar
Filing Date: June, 29 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: June, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: June, 27 2018

 

 


Daily Technical Chart for (NASDAQ: ACST)

Daily Technical Chart for (NASDAQ: ACST)


Stay tuned for daily updates and more on (NASDAQ: ACST)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ACST)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ACST is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ACST and does not buy, sell, or trade any shares of ACST. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/